lunes, 17 de septiembre de 2012

Screening for Ovarian Cancer: Clinical Summary of USPSTF Recommendation

Screening for Ovarian Cancer: Clinical Summary of USPSTF Recommendation

U.S. Preventive Services 

Task Force banner
U.S. Preventive Services Task Force

Screening for Ovarian Cancer

Clinical Summary of U.S. Preventive Services Task Force Reaffirmation Recommendation

Release Date: September 2012

Population Asymptomatic women without known genetic mutations that increase risk for ovarian cancer
Recommendation Do not screen for ovarian cancer. Grade: D
Risk Assessment Women with BRCA1 and BRCA2 genetic mutations, the Lynch syndrome (hereditary nonpolyposis colon cancer), or a family history of ovarian cancer are at increased risk for ovarian cancer. Women with an increased-risk family history should be considered for genetic counseling to further evaluate their potential risks. “Increased-risk family history” generally means having 2 or more first- or second-degree relatives with a history of ovarian cancer or a combination of breast and ovarian cancer; for women of Ashkenazi Jewish descent, it means having a first-degree relative (or 2 second-degree relatives on the same side of the family) with breast or ovarian cancer.
Screening Tests Transvaginal ultrasonography and serum cancer antigen (CA)–125 testing are the most commonly suggested screening modalities.
Treatments Treatment of ovarian carcinoma includes surgical treatment (debulking) and intraperitoneal or systemic chemotherapy.
Balance of Benefits and Harms Annual screening with transvaginal ultrasonography and serum CA-125 testing in women does not decrease ovarian cancer mortality. Screening for ovarian cancer can lead to important harms, including major surgical interventions in women who do not have cancer.
Therefore, the harms of screening for ovarian cancer outweigh the benefits.
Relevant USPSTF Recommendations The USPSTF has made a recommendation on genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. This recommendation is available at
For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
AHRQ Publication No. 12-05165-EF-5
Current as of September 2012

Internet Citation:
Screening for Ovarian Cancer: Clinical Summary of U.S. Preventive Services Task Force Reaffirmation Recommendation. AHRQ Publication No. 12-05165-EF-5, September 2012.

No hay comentarios:

Publicar un comentario